Clinical Advances in

Targeting DNA Damage Response

As research advances, we continue to expand our knowledge and understanding of novel targets in DNA damage response as potential therapeutic options in oncology. While PARP inhibitors have led the way, and are increasingly being recognized as a targeted therapeutic approach for patients with BRCA mutations and other indicators of susceptibility, agents targeting different DNA damage response pathways may potentially reshape the treatment landscape in oncology in the near future.

This curriculum explores the recent clinical advances with agents targeting different aspects of DNA damage response, their rationale for use, and emerging clinical data.

CME Activities

Polling Question

Related Resources

Downloadable Slide Kit

Homologous Recombination Repair and BRCA

Download

Clinical Articles

Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.

The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review.

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions

Steering Committee

Don S. Dizon, MD

Steering Committee Chair

Clinical Co-Director, Gynecologic Oncology; Director, The Oncology Sexual Health Clinic, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Robert L. Coleman, MD

Professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas

Mark E. Robson, MD

Clinic Director, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York

Elizabeth Swisher, MD

Professor, Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington

Richard T. Penson, MD, MRCP

Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Massachusetts General Hospital, Boston, Massachusetts

Kimberly L. Blackwell, MD

Professor of Medicine, Duke University Medical Center, Durham, North Carolina

	How confident are you in managing grade 2 nausea in a patient with advanced ovarian cancer receiving PARP inhibitor therapy?
		Very confident
		Somewhat confident
		Neither confident nor unsure
		Somewhat unsure
		Very unsure